AYTU
Aytu BioPharma, Inc.
Price Chart
Latest Quote
$2.10
+0.02 (+1.20%)
Current Price
| Previous Close | $2.08 |
| Open | $2.17 |
| Day High | $2.17 |
| Day Low | $2.09 |
| Volume | 5,342 |
Stock Information
| Shares Outstanding | 10.73M |
| Total Debt | $21.82M |
| Cash Equivalents | $26.71M |
| Revenue | $56.60M |
| Net Income | $-34.12M |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market Cap | $22.59M |
| EPS (TTM) | $-4.61 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $17.43M |
| Sales | $56.60M |
| Income | $-34.12M |
| Book/sh | $3.27 |
| Cash/sh | $2.49 |
| Employees | 82 |
Financial Ratios
| Quick Ratio | 0.85 |
| Current Ratio | 1.12 |
| Debt/Eq | 62.08 |
Returns & Margins
| ROA | -3.65% |
| ROE | -97.42% |
| Gross Margin | 64.78% |
| Operating Margin | -32.74% |
| Profit Margin | -60.17% |
Ownership
| Insider Ownership | 8.98% |
| Institutional Ownership | 36.58% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -28.07 |
| P/S | 0.40 |
| P/B | 0.64 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $9.50 |
Technical Indicators
| SMA20 | $2.18 |
| SMA50 | $2.36 |
| SMA200 | $2.38 |
| RSI | 41.61 |
| ATR | 0.1072 |
| Shares Float | 7.61M |
| Short Float | 4.43% |
| Short Ratio | 7.58 |
| Rel Volume | 0.17 |
Performance History
| Week | -6.03% |
| Month | +0.24% |
| Quarter | -19.04% |
| 6 Months | -9.66% |
| YTD | -24.01% |
| Year | +6.31% |
| 3 Years | +26.05% |
| 5 Years | -98.02% |
| 10 Years | -100.00% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-17 | $2.11 | 5,342 |
| 2026-06-16 | $2.08 | 81,100 |
| 2026-06-15 | $2.20 | 11,400 |
| 2026-06-12 | $2.15 | 14,400 |
| 2026-06-11 | $2.19 | 15,400 |
| 2026-06-10 | $2.24 | 13,400 |
| 2026-06-09 | $2.30 | 35,500 |
| 2026-06-08 | $2.29 | 21,100 |
| 2026-06-05 | $2.25 | 65,500 |
| 2026-06-04 | $2.12 | 16,200 |
| 2026-06-03 | $2.09 | 29,900 |
| 2026-06-02 | $2.10 | 41,000 |
| 2026-06-01 | $2.15 | 67,500 |
| 2026-05-29 | $2.29 | 46,100 |
| 2026-05-28 | $2.24 | 10,100 |
| 2026-05-27 | $2.21 | 24,400 |
| 2026-05-26 | $2.18 | 40,100 |
| 2026-05-22 | $2.19 | 20,600 |
| 2026-05-21 | $2.13 | 27,700 |
| 2026-05-20 | $2.15 | 29,500 |
| 2026-05-19 | $2.08 | 119,500 |
| 2026-05-18 | $2.10 | 105,500 |
About Aytu BioPharma, Inc.
Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT extended-release orally disintegrating tablets for patients from six to seventeen years old; and Metadate CD, a central nervous system stimulant indicated for the treatment of ADHD. It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu BioPharma, Inc. in March 2021. Aytu BioPharma, Inc. is headquartered in Denver, Colorado.
đ° Latest News
Aytu BioPharma, Inc. Q3 2026 Earnings Call Summary
Moby âĸ 2026-05-14T12:30:00Z
Aytu BioPharma Inc (AYTU) Q3 2026 Earnings Call Highlights: Strong Exua Adoption Amid Revenue ...
GuruFocus.com âĸ 2026-05-14T05:02:13ZAytu (AYTU) Q3 2026 Earnings Transcript
Motley Fool âĸ 2026-05-13T21:54:48Z
Full Transcript: Aytu BioPharma Q3 2026 Earnings Call
Benzinga âĸ 2026-05-13T21:39:38Z
Aytu BioPharma, Inc. (AYTU) Reports Q3 Loss, Tops Revenue Estimates
Zacks âĸ 2026-05-13T21:35:02Z
Immatics (IMTX) Reports Q1 Loss, Lags Revenue Estimates
Zacks âĸ 2026-05-12T12:25:02Z
Puma Biotech (PBYI) Reports Q1 Loss, Tops Revenue Estimates
Zacks âĸ 2026-05-07T23:05:04Z
Favourable Signals For Aytu BioPharma: Numerous Insiders Acquired Stock
Simply Wall St. âĸ 2026-04-30T12:53:35Z
Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Shift From Loss To Profit
Simply Wall St. âĸ 2026-02-05T10:56:17Z
Aytu BioPharma Inc (AYTU) Q2 2026 Earnings Call Highlights: Navigating Challenges and ...
GuruFocus.com âĸ 2026-02-04T05:02:32Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $18,857,000 | $13,087,000 | $36,740,000 | $40,084,000 |
| Cost Of Revenue | $20,551,000 | $16,129,000 | $40,767,000 | $44,386,000 |
| Total Revenue | $66,382,000 | $65,183,000 | $107,399,000 | $96,669,000 |
| Operating Revenue | $66,382,000 | $65,183,000 | $107,399,000 | $96,669,000 |
| Expenses | ||||
| Interest Expense | $3,703,000 | $5,059,000 | $4,963,000 | - |
| Total Expenses | $63,845,000 | $64,618,000 | $119,728,000 | $132,772,000 |
| Other Income Expense | $-12,579,000 | $-5,884,000 | $241,000 | $-72,786,000 |
| Other Non Operating Income Expenses | $-512,000 | $870,000 | $184,000 | $-757,000 |
| Net Non Operating Interest Income Expense | $-3,703,000 | $-5,059,000 | $-4,963,000 | - |
| Interest Expense Non Operating | $3,703,000 | $5,059,000 | $4,963,000 | - |
| Operating Expense | $43,294,000 | $48,489,000 | $78,961,000 | $88,386,000 |
| Selling And Marketing Expense | $20,906,000 | $22,083,000 | $41,448,000 | $38,713,000 |
| General And Administrative Expense | $17,379,000 | $19,954,000 | $28,630,000 | $31,167,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-14,182,000 | $-12,520,000 | $-17,051,000 | $-108,779,000 |
| Net Interest Income | $-3,703,000 | $-5,059,000 | $-4,963,000 | - |
| Normalized Income | $-4,649,070 | $-7,184,340 | $-17,108,000 | $-36,814,826 |
| Net Income From Continuing And Discontinued Operation | $-13,562,000 | $-15,844,000 | $-17,051,000 | $-108,779,000 |
| Total Operating Income As Reported | $-7,827,000 | $-1,591,000 | $-17,065,000 | $-109,906,000 |
| Net Income Common Stockholders | $-13,562,000 | $-15,844,000 | $-17,051,000 | $-108,779,000 |
| Net Income | $-13,562,000 | $-15,844,000 | $-17,051,000 | $-108,779,000 |
| Net Income Including Noncontrolling Interests | $-13,562,000 | $-15,844,000 | $-17,051,000 | $-108,779,000 |
| Net Income Discontinuous Operations | $620,000 | $-3,324,000 | - | - |
| Net Income Continuous Operations | $-14,182,000 | $-12,520,000 | $-17,051,000 | $-108,779,000 |
| Pretax Income | $-13,745,000 | $-10,378,000 | $-17,051,000 | $-108,889,000 |
| Special Income Charges | $-10,364,000 | $-2,750,000 | $-4,736,000 | $-73,634,000 |
| Operating Income | $2,537,000 | $565,000 | $-12,329,000 | $-36,103,000 |
| Depreciation Amortization Depletion Income Statement | $3,683,000 | $3,683,000 | $4,788,000 | $5,844,000 |
| Depreciation And Amortization In Income Statement | $3,683,000 | $3,683,000 | $4,788,000 | $5,844,000 |
| Amortization Of Intangibles Income Statement | $3,683,000 | $3,683,000 | $4,788,000 | $5,844,000 |
| Gross Profit | $45,831,000 | $49,054,000 | $66,632,000 | $52,283,000 |
| Per Share | ||||
| Diluted EPS | $-2.16 | $-2.86 | $-5.11 | $-75.00 |
| Basic EPS | $-2.16 | $-2.86 | $-5.11 | $-75.00 |
| Other | ||||
| Tax Effect Of Unusual Items | $-2,534,070 | $-1,418,340 | $0 | $-64,826 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $7,402,000 | $8,160,000 | $-3,330,000 | $46,072,000 |
| Total Unusual Items | $-12,067,000 | $-6,754,000 | $57,000 | $-72,029,000 |
| Total Unusual Items Excluding Goodwill | $-12,067,000 | $-6,754,000 | $57,000 | $-72,029,000 |
| Reconciled Depreciation | $5,377,000 | $6,725,000 | $8,815,000 | $10,146,000 |
| EBITDA (Bullshit earnings) | $-4,665,000 | $1,406,000 | $-3,273,000 | $-25,957,000 |
| EBIT | $-10,042,000 | $-5,319,000 | $-12,088,000 | $-36,103,000 |
| Diluted Average Shares | $6,279,744 | $5,537,957 | $3,339,906 | $1,469,875 |
| Basic Average Shares | $6,279,744 | $5,537,957 | $3,339,906 | $1,469,875 |
| Diluted NI Availto Com Stockholders | $-13,562,000 | $-15,844,000 | $-17,051,000 | $-108,779,000 |
| Tax Provision | $437,000 | $2,142,000 | $0 | $-110,000 |
| Write Off | $8,263,000 | $0 | $5,705,000 | $9,656,000 |
| Restructuring And Mergern Acquisition | $2,101,000 | $2,156,000 | $-969,000 | $-1,655,000 |
| Gain On Sale Of Security | $-1,703,000 | $-4,004,000 | $4,793,000 | $1,605,000 |
| Amortization | $3,683,000 | $3,683,000 | $4,788,000 | $5,844,000 |
| Research And Development | $1,326,000 | $2,769,000 | $4,095,000 | $12,662,000 |
| Selling General And Administration | $38,285,000 | $42,037,000 | $70,078,000 | $69,880,000 |
| Other Gand A | $17,379,000 | $19,954,000 | $28,630,000 | $31,167,000 |
| Other Special Charges | - | $594,000 | - | $-169,000 |
| Impairment Of Capital Assets | - | - | $0 | $65,802,000 |
Fetched: 2026-06-15
Balance Sheet (Annual)
| Metric | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-23,235,000 | $-24,737,000 | $-19,613,000 | $-26,324,000 |
| Total Assets | $124,177,000 | $118,095,000 | $136,463,000 | $137,623,000 |
| Total Non Current Assets | $44,998,000 | $56,204,000 | $65,384,000 | $77,694,000 |
| Other Non Current Assets | $1,204,000 | $2,229,000 | $2,545,000 | $766,000 |
| Goodwill And Other Intangible Assets | $42,201,000 | $52,453,000 | $58,970,000 | $70,632,000 |
| Other Intangible Assets | $42,201,000 | $52,453,000 | $58,970,000 | $70,632,000 |
| Current Assets | $79,179,000 | $61,891,000 | $71,079,000 | $59,929,000 |
| Other Current Assets | $5,638,000 | $5,097,000 | $7,162,000 | $8,008,000 |
| Assets Held For Sale Current | $0 | $1,121,000 | - | - |
| Inventory | $11,434,000 | $12,141,000 | $11,995,000 | $10,849,000 |
| Receivables | $31,155,000 | $23,526,000 | $28,937,000 | $21,712,000 |
| Accounts Receivable | $31,155,000 | $23,526,000 | $28,937,000 | $21,712,000 |
| Allowance For Doubtful Accounts Receivable | $-1,188,000 | $-1,822,000 | $-2,990,000 | $0 |
| Gross Accounts Receivable | $32,343,000 | $25,348,000 | $31,927,000 | $21,712,000 |
| Cash Cash Equivalents And Short Term Investments | $30,952,000 | $20,006,000 | $22,985,000 | $19,360,000 |
| Cash And Cash Equivalents | $30,952,000 | $20,006,000 | $22,985,000 | $19,360,000 |
| Prepaid Assets | - | - | $8,047,000 | $7,375,000 |
| Restricted Cash | - | - | - | $0 |
| Debt | ||||
| Total Debt | $21,815,000 | $15,129,000 | $16,361,000 | $18,188,000 |
| Long Term Debt And Capital Lease Obligation | $10,895,000 | $10,877,000 | $14,713,000 | $14,279,000 |
| Long Term Debt | $10,895,000 | $10,877,000 | $14,713,000 | $14,279,000 |
| Current Debt And Capital Lease Obligation | $10,920,000 | $4,252,000 | $1,648,000 | $3,909,000 |
| Current Debt | $10,920,000 | $4,252,000 | $1,648,000 | $3,909,000 |
| Other Current Borrowings | $1,857,000 | $1,857,000 | $85,000 | $96,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $105,211,000 | $90,379,000 | $97,106,000 | $93,315,000 |
| Total Non Current Liabilities Net Minority Interest | $42,147,000 | $28,151,000 | $28,091,000 | $28,873,000 |
| Other Non Current Liabilities | $4,918,000 | $4,529,000 | $6,975,000 | $12,798,000 |
| Derivative Product Liabilities | $26,334,000 | $12,745,000 | $6,403,000 | $1,796,000 |
| Current Liabilities | $63,064,000 | $62,228,000 | $69,015,000 | $64,442,000 |
| Other Current Liabilities | $3,379,000 | $9,519,000 | $7,090,000 | $5,359,000 |
| Payables And Accrued Expenses | $38,822,000 | $39,022,000 | $48,825,000 | $44,639,000 |
| Payables | $10,601,000 | $10,314,000 | $13,478,000 | $10,987,000 |
| Accounts Payable | $10,601,000 | $10,314,000 | $13,478,000 | $10,987,000 |
| Equity | ||||
| Common Stock Equity | $18,966,000 | $27,716,000 | $39,357,000 | $44,308,000 |
| Total Equity Gross Minority Interest | $18,966,000 | $27,716,000 | $39,357,000 | $44,308,000 |
| Stockholders Equity | $18,966,000 | $27,716,000 | $39,357,000 | $44,308,000 |
| Retained Earnings | $-333,535,000 | $-319,973,000 | $-304,129,000 | $-287,078,000 |
| Other | ||||
| Ordinary Shares Number | $8,976,913 | $5,972,638 | $5,517,174 | $1,928,941 |
| Share Issued | $8,976,913 | $5,972,638 | $5,517,174 | $1,928,941 |
| Tangible Book Value | $-23,235,000 | $-24,737,000 | $-19,613,000 | $-26,324,000 |
| Invested Capital | $40,781,000 | $42,845,000 | $55,718,000 | $62,496,000 |
| Working Capital | $16,115,000 | $-337,000 | $2,064,000 | $-4,513,000 |
| Total Capitalization | $29,861,000 | $38,593,000 | $54,070,000 | $58,587,000 |
| Additional Paid In Capital | $352,500,000 | $347,688,000 | $343,485,000 | $331,386,000 |
| Capital Stock | $1,000 | $1,000 | $1,000 | $0 |
| Common Stock | $1,000 | $1,000 | $1,000 | $0 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Line Of Credit | $9,063,000 | $2,395,000 | $1,563,000 | $3,813,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $3,132,000 | $4,603,000 | $5,675,000 | $4,765,000 |
| Current Provisions | $6,811,000 | $4,832,000 | $5,777,000 | $5,770,000 |
| Current Accrued Expenses | $28,221,000 | $28,708,000 | $35,347,000 | $33,652,000 |
| Net PPE | $1,593,000 | $1,522,000 | $3,869,000 | $6,296,000 |
| Accumulated Depreciation | $-714,000 | $-2,125,000 | $-3,681,000 | $-2,421,000 |
| Gross PPE | $2,307,000 | $3,647,000 | $7,550,000 | $8,717,000 |
| Leases | $164,000 | $35,000 | $999,000 | $999,000 |
| Other Properties | $1,869,000 | $2,667,000 | $5,319,000 | $6,590,000 |
| Machinery Furniture Equipment | $274,000 | $945,000 | $1,125,000 | $1,128,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $8,938,000 | $6,150,000 | $7,738,000 | $7,197,000 |
| Work In Process | $1,381,000 | $5,725,000 | $2,956,000 | $1,838,000 |
| Raw Materials | $1,115,000 | $266,000 | $1,301,000 | $1,814,000 |
| Construction In Progress | - | $0 | $107,000 | $0 |
| Goodwill | - | - | - | $0 |
| Capital Lease Obligations | - | - | - | - |
| Long Term Capital Lease Obligation | - | - | - | - |
| Current Capital Lease Obligation | - | - | - | - |
Fetched: 2026-06-15
Cash Flow Statement (Annual)
| Metric | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-5,165,000 | $-1,717,000 | $-5,129,000 | $-28,823,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-1,937,000 | $-1,388,000 | $-5,129,000 | $-28,823,000 |
| Cash Flow From Continuing Operating Activities | $-1,937,000 | $-1,388,000 | $-5,129,000 | $-28,823,000 |
| Operating Gains Losses | $1,703,000 | $4,404,000 | $-4,793,000 | $-373,000 |
| Investing Activities | ||||
| Capital Expenditure | $-3,228,000 | $-329,000 | - | - |
| Investing Cash Flow | $-2,560,000 | $-329,000 | $-117,000 | $-3,248,000 |
| Cash Flow From Continuing Investing Activities | $-2,560,000 | $-329,000 | $-117,000 | $-3,248,000 |
| Net Other Investing Changes | - | $-329,000 | $-117,000 | $-70,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $14,840,000 | $3,467,000 | $15,575,000 | $11,694,000 |
| Financing Cash Flow | $15,443,000 | $-1,262,000 | $8,871,000 | $1,530,000 |
| Cash Flow From Continuing Financing Activities | $15,443,000 | $-1,262,000 | $8,871,000 | $1,530,000 |
| Net Other Financing Charges | $-6,065,000 | $-2,839,000 | $-4,358,000 | $-4,942,000 |
| Net Common Stock Issuance | $14,840,000 | $3,467,000 | $15,575,000 | $11,694,000 |
| Common Stock Issuance | $14,840,000 | $3,467,000 | $15,575,000 | $11,694,000 |
| Other | ||||
| Repayment Of Debt | $-1,857,000 | $-15,722,000 | $-2,346,000 | $-20,222,000 |
| Issuance Of Debt | $8,525,000 | $13,832,000 | $0 | $15,000,000 |
| Interest Paid Supplemental Data | $2,822,000 | $4,039,000 | $3,812,000 | $3,148,000 |
| Income Tax Paid Supplemental Data | $1,419,000 | $1,608,000 | $0 | - |
| End Cash Position | $30,952,000 | $20,006,000 | $22,985,000 | $19,360,000 |
| Beginning Cash Position | $20,006,000 | $22,985,000 | $19,360,000 | $49,901,000 |
| Changes In Cash | $10,946,000 | $-2,979,000 | $3,625,000 | $-30,541,000 |
| Net Issuance Payments Of Debt | $6,668,000 | $-1,890,000 | $-2,346,000 | $-5,222,000 |
| Net Short Term Debt Issuance | $6,668,000 | $832,000 | $-2,250,000 | $-4,121,000 |
| Short Term Debt Issuance | $6,668,000 | $832,000 | - | $152,236,000 |
| Net Long Term Debt Issuance | $0 | $-2,722,000 | $-96,000 | $-1,101,000 |
| Long Term Debt Payments | $-1,857,000 | $-15,722,000 | $-96,000 | $-16,101,000 |
| Long Term Debt Issuance | $1,857,000 | $13,000,000 | $0 | $15,000,000 |
| Net Intangibles Purchase And Sale | $-3,000,000 | $0 | - | - |
| Purchase Of Intangibles | $-3,000,000 | $0 | - | - |
| Net PPE Purchase And Sale | $440,000 | $-329,000 | - | - |
| Sale Of PPE | $668,000 | $0 | - | - |
| Purchase Of PPE | $-228,000 | $-329,000 | - | - |
| Change In Working Capital | $-5,733,000 | $-4,660,000 | $-5,799,000 | $-10,863,000 |
| Change In Other Working Capital | $792,000 | $5,868,000 | $-1,872,000 | $50,000 |
| Change In Payables And Accrued Expense | $1,173,000 | $-11,237,000 | $5,989,000 | $-20,973,000 |
| Change In Accrued Expense | $886,000 | $-9,161,000 | $3,605,000 | $-13,292,000 |
| Change In Payable | $287,000 | $-2,076,000 | $2,384,000 | $-7,681,000 |
| Change In Account Payable | $287,000 | $-2,076,000 | $2,384,000 | $-7,681,000 |
| Change In Prepaid Assets | $-451,000 | $329,000 | $846,000 | $2,228,000 |
| Change In Inventory | $382,000 | $-4,821,000 | $-3,609,000 | $1,299,000 |
| Change In Receivables | $-7,629,000 | $5,201,000 | $-7,153,000 | $6,533,000 |
| Changes In Account Receivables | $-7,629,000 | $5,201,000 | $-7,153,000 | $6,533,000 |
| Other Non Cash Items | $1,114,000 | $4,425,000 | $-403,000 | $-1,846,000 |
| Stock Based Compensation | $576,000 | $2,373,000 | $6,046,000 | $5,248,000 |
| Asset Impairment Charge | $8,588,000 | $1,189,000 | $8,056,000 | $77,644,000 |
| Depreciation Amortization Depletion | $5,377,000 | $6,725,000 | $8,815,000 | $10,146,000 |
| Depreciation And Amortization | $5,377,000 | $6,725,000 | $8,815,000 | $10,146,000 |
| Depreciation | $5,377,000 | $6,725,000 | $8,815,000 | $10,146,000 |
| Gain Loss On Investment Securities | $1,703,000 | $4,004,000 | $-4,793,000 | $-180,000 |
| Net Income From Continuing Operations | $-13,562,000 | $-15,844,000 | $-17,051,000 | $-108,779,000 |
| Short Term Debt Payments | - | - | $-2,250,000 | $-4,121,000 |
| Net Business Purchase And Sale | - | - | $-5,000 | $-3,178,000 |
| Purchase Of Business | - | - | $-5,000 | $-3,178,000 |
| Sale Of Business | - | - | - | $0 |
| Provisionand Write Offof Assets | - | - | - | $-69,000 |
| Proceeds From Stock Option Exercised | - | - | - | - |
Fetched: 2026-06-15